green
Positive treatment
6.2 score
Treatment trajectory · 1998 → 2026 · click a year to view as-of
1998
2012
2026
Top citers, strongest first. 27 distinct citers.
How cited ↗
cited
Cited "see"
Cunningham v. Haroona
See Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706, 714-15 (Tex.1997), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998); see also Faust v. BNSF Ry.
cited
Cited "see"
Robert Gene Cunningham, Individually and as Representative of the Estate of Patricia Maudine Cunningham, Robin Lee Cunningham Bishop, and Tracy Jeanne Cunningham Lang v. Ladi O.M. Haroona, M.D.
See Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706 , 714–15 (Tex. 1997), cert. denied, 523 U.S. 1119 (1998); see also Faust v. BNSF Ry.
cited
Cited "see"
Robert Gene Cunningham, Individually and as Representative of the Estate of Patricia Maudine Cunningham, Robin Lee Cunningham Bishop, and Tracy Jeanne Cunningham Lang v. Ladi O.M. Haroona, M.D.
See Merrell Dow Pharm., Inc. v. Havner , 953 S.W.2d 706 , 714–15 (Tex. 1997), cert. denied , 523 U.S. 1119 (1998); see also Faust v. BNSF Ry.
cited
Cited "see"
Smith v. KELLY-MOORE PAINT CO., INC.
See Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706, 714 (Tex.1997), ce rt. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998); Georgia-Pac.
cited
Cited "see"
Rosemary Smith, Brady Smith, and Donna Hubbard, Individually and as Personal Representative of the Heirs and Estate of Dorman Smith v. Kelly-Moore Paint Company, Inc.
See Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706, 714 (Tex. 1997), cert. denied, 523 U.S. 1119 (1998); Georgia Pac.
cited
Cited "see"
Rosemary Smith, Brady Smith, and Donna Hubbard, Individually and as Personal Representative of the Heirs and Estate of Dorman Smith v. Kelly-Moore Paint Company, Inc.
See Merrell Dow Pharm., Inc. v. Havner , 953 S.W.2d 706, 714 (Tex. 1997), cert. denied , 523 U.S. 1119 (1998); Georgia Pac.
cited
Cited "see"
In Re the Expunction of J.A.
See Merrell Dow Pharmaceuticals, Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see"
City of Houston v. Fletcher
Southwest Key Program, Inc. v. Gil-Perez, 81 S.W.3d 269, 274 (Tex.2002); Garza v. Alviar, 395 S.W.2d 821, 823 (Tex.1965); see Merrell Dow Pharmaceuticals, Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. den’d, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see"
Primrose Operating Co., Inc. v. Senn
Southwest Key Program, Inc. v. Gil-Perez, 81 S.W.3d 269, 274 (Tex.2002); Garza v. Alviar, 395 S.W.2d 821, 823 (Tex.1965); see Merrell Dow Pharmaceuticals, Inc. v. Hamer, 953 S.W.2d 706, 711 (Tex.1997), cert. den’d, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see"
Eugene Carl Sanders v. Home Depot U.S.A., Inc. and Jan Patterson
See Merrell Dow Pharms., Inc. v. Havner, 953 S.W.2d 706, 720 (Tex. 1997) (holding that plaintiff must present reliable evidence to establish fact issue regarding causation), cert. denied, 523 U.S. 1119 (1998); E.I. du Pont de Nemours & Co. v. Robinson, 923 S.W.2d 549, 553-54 (Tex. 1995) (stating that trial courts must ensure that expert testimony is reliable before admitting it); see also Tex. R.
discussed
Cited "see"
Eugene Carl Sanders v. Home Depot U.S.A., Inc. and Jan Patterson
Evid. 702, 704; see also Birchfield v. Texarkana Mem’l Hosp., 747 S.W.2d 361, 365 (Tex. 1987) (holding that expert may state opinion on mixed question of law and fact as long as opinion is confined to relevant issues and based on proper legal concepts). 4: See Merrell Dow Pharms., Inc. v. Havner, 953 S.W.2d 706, 720 (Tex. 1997) (holding that plaintiff must present reliable evidence to establish fact issue regarding causation), cert. denied, 523 U.S. 1119 (1998); E.I. du Pont de Nemours & Co. v. Robinson, 923 S.W.2d 549, 553-54 (Tex. 1995) (stating that trial courts must ensure that expert te…
discussed
Cited "see"
Cannon v. Sun-Key Oil Co., Inc.
Southwest Key Program, Inc. v. Gil-Perez, 81 S.W.3d 269, 274 (Tex.2002); Garza v. Alviar, 395 S.W.2d 821, 823 (Tex.1965); see Merrell Dow Pharmaceuticals, Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. den’d, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see"
Al Ellis v. City of Dallas
Southwest Key Program, Inc. v. Gil-Perez, 81 S.W.3d 269, 274 (Tex.2002); Garza v. Alviar, 395 S.W.2d 821, 823 (Tex.1965); see Merrell Dow Pharmaceuticals, Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. den = d , 523 U.S. 1119 (1998).
discussed
Cited "see"
Ellis v. City of Dallas
Southwest Key Program, Inc. v. Gil-Perez, 81 S.W.3d 269, 274 (Tex.2002); Garza v. Alviar, 395 S.W.2d 821, 823 (Tex.1965); see Merrell Dow Pharmaceuticals, Inc. v. Hamer, 953 S.W.2d 706, 711 (Tex.1997), cert, den’d, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see"
Soldo v. Sandoz Pharmaceuticals Corp.
See [Merrell Dow Pharm., Inc. v.] Havner, 953 S.W.2d [706], 718, 724 [Tex. 1997], cert. denied, [ 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 ] (1998).”) 8 *539 54.Similarly, the Court of Appeals for the Third Circuit and district courts therein have held that adverse event reporting system data are not a legitimate basis for causation opinions involving pharmaceutical products.
cited
Cited "see"
Elgaghil v. Tarrant County Junior College
See Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998); Moore, 981 S.W.2d at 269 .
cited
Cited "see"
Nowroozi, Michael v. Strozier, Scott, Sam Stiefel, Nancy Walker & Tom Burslem
See Merrill Dow Pharm., Inc. v. Havner , 953 S.W.2d 706, 711 (Tex.1997), cert. denied , 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see"
Texas Workers' Compensation Insurance Fund v. Lopez
Robinson, 923 S.W.2d at 557 ; see Merrell Dow Pharm. v. Havner, 953 S.W.2d 706, 714 (Tex.1997), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998); see also Garcia, 974 S.W.2d at 85 .
discussed
Cited "see, e.g."
Acadia Healthcare Company, Inc. Psychiatric Resource Partners, Inc. Michael A. Saul Timothy J. Palus Peter D. Ulasewicz Barbara H. Bayma And John M. Piechocki v. Horizon Health Corporation
See, e.g., Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706, 714 (Tex. 1997) (“[A]n expert’s testimony is unreliable even when the underlying data are sound if the expert draws conclusions from that data based on flawed methodology.”), cert. denied, 523 U.S. 1119 (1998). 14 No objection is required to argue on appeal that, on the face of the record, the testimony is conclusory and speculative and therefore lacks probative value.
discussed
Cited "see, e.g."
Acadia Healthcare Co. v. Horizon Health Corp.
See, e.g., Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706, 714 (Tex.1997) ("[A]n expert’s testimony is unreliable even when the underlying data are sound if the expert draws conclusions from that data based on flawed methodology.’’), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998). .No objection is required to argue on appeal that, on the face of the record, the testimony is conclusory and speculative and therefore lacks probative value.
discussed
Cited "see, e.g."
Acadia Healthcare Company, Inc. Psychiatric Resource Partners, Inc. Michael A. Saul Timothy J. Palus Peter D. Ulasewicz Barbara H. Bayma And John M. Piechocki v. Horizon Health Corporation
See, e.g., Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706, 714 (Tex. 1997) (“[A]n expert’s testimony is unreliable even when the underlying data are sound if the expert draws conclusions from that data based on flawed methodology.”), cert. denied, 523 U.S. 1119 (1998). 16 on appeal that the evidence is unreliable. 15 Maritime Overseas Corp. v. Ellis, 971 S.W.2d 402, 409 (Tex.), cert. denied, 525 U.S. 1017 (1998); Faust v. BNSF Ry.
discussed
Cited "see, e.g."
South Plains Lamesa Railroad, Ltd. v. Acero International, Inc.
Juliette Fowler Homes, Inc. v. Welch Associates, Inc., 793 S.W.2d 660 (Tex.1990); In re King's Estate, 244 S.W.2d 660 (Tex.1951); see also Merrell Dow Pharmaceuticals, Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. den'd , 523 U.S. 1119 (1998).
discussed
Cited "see, e.g."
Myers v. Walker
Weirich v. Weirich, 833 S.W.2d 942, 945 (Tex.1992); In re King’s Estate, 150 Tex. 662 , 244 S.W.2d 660 (Tex.1951); see also Merrell Dow Pharmaceuticals, Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. den’d, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see, e.g."
Christian Academy of Abilene v. City of Abilene
Juliette Fowler Homes, Inc. v. Welch Associates, Inc., 793 S.W.2d 660 (Tex.1990); In re King’s Estate, 150 Tex. 662 , 244 S.W.2d 660 (1951); see also Merrell Dow Pharmaceuticals, Inc. v. Havner, 953 S.W.2d 706, 711 (Tex.1997), cert. den’d, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998).
discussed
Cited "see, e.g."
Wright v. Bowie Memorial Hospital
(2×)
See, e.g., Merrell Dow Pharms., Inc. v. Havner, 953 S.W.2d 706, 711-12 (Tex. 1997), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998); Duff v. Yelin, 751 S.W.2d 175, 176 (Tex.1988).
discussed
Cited "see, e.g."
In Re DS
EVID. 702; see also Merrell Dow Pharms., Inc. v. Havner, 953 S.W.2d 706, 712 (Tex.1997), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998); Lincoln Property Co. v. DeShazo, 4 S.W.3d 55, 58 (Tex.App.-Fort Worth *529 1999, pet. denied).
discussed
Cited "see, e.g."
In the Interest of D.S.
EVID. 702; see also Merrell Dow Pharms., Inc. v. Havner, 953 S.W.2d 706, 712 (Tex.1997), cert. denied, 523 U.S. 1119 , 118 S.Ct. 1799 , 140 L.Ed.2d 939 (1998); Lincoln Property Co. v. DeShazo, 4 S.W.3d 55, 58 (Tex.App.—Fort Worth 1999, pet. denied).
Retrieving the full opinion text from the archive…
Diaz, Personal Representative of the Estate of Diaz, and on Behalf of Diaz
v.
CCHC-Golden Glades, Ltd.
v.
CCHC-Golden Glades, Ltd.
No. 97-1479.
Supreme Court of the United States.
May 18, 1998.
Published
Dist. Ct. App. Fla., 3d Dist. Certiorari denied.